Norway· NO-ID_A5E9E615-F21F-4E91-80A2-A71918E18D3F
Fintepla
A fenfluramine product containing fenfluramine hydrochloride, registered in Norway by UCB Pharma S.A.. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Fenfluramine is registered in 11 of 19 countries.
Countries holding a registration under ATC N03AX26 (fenfluramine), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Fenfluramine · ATC N03AX26
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Fenfluramine Hydrochloride
- Manufacturer
- UCB Pharma S.A.
- Country
- Norway (NO)
- ATC code
- N03AX26
- ATC class
- Fenfluramine
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 5
2 priced- no_merkevare_idID_A5E9E615-F21F-4E91-80A2-A71918E18D3F
- no_varenummer042540360NOK 69749.9
- no_varenummer419591120NOK 23290
- gtin5413787222131
- gtin5413787222124
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
349 interactions on record for fenfluramine.
Graded by severity as the source publishes them — 85 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fenfluramine · interactions on record
349 records
- 85 severe
- 260 moderate
- 4 minor
Most severe, free to view
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- DolasetronA04AA04severe
- PalonosetronA04AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fenfluramine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaFINTEPLAUCB Pharma SA, Brusel
- SwitzerlandFintepla 2.2 mg/ml, solution buvableUCB-Pharma SA
- FinlandFinteplaUCB S.A.
- FranceFINTEPLA 2,2 mg/mL, solution buvableUCB PHARMA BELGIQUE
- IrelandFintepla 2.2 mg/ml oral solutionUCB Pharma S.A.
- IcelandFinteplaUCB Pharma S.A.*
- NetherlandsFintepla 2,2 mg/ml drankUCB Pharma S.A.
- PolandFinteplaUCB Pharma S.A.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Fintepla
- Liechtenstein · Fintepla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6cb6d3ff-5d9e-4f19-adf4-bea5ae8a28d4 GET /v1/drugs/6cb6d3ff-5d9e-4f19-adf4-bea5ae8a28d4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Mikstur, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Fenfluramin",
"merkevare_id": "ID_A5E9E615-F21F-4E91-80A2-A71918E18D3F",
"name_form_strength": "Fintepla mikst oppl 2,2 mg/ml",
"prescription_group": "B"
}See everything about fenfluramine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.